MedTrace Logo

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

NCT07141563 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-01-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the real-world effectiveness and safety of neoadjuvant nivolumab combined with chemotherapy in Argentinian patients with resectable non-small cell lung cancer (NSCLC)

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Nivolumab + platinum-based chemotherapy

According to the product label

Sponsors & Collaborators

  • Grupo Argentino Oncología Torácica (GAOT) - Asociación Argentina Oncología Clínica (AAOC)

    collaborator UNKNOWN

  • Bristol-Myers Squibb

    lead INDUSTRY

Principal Investigators

  • Aldo Perfetti, MD · Asociación Argentina Oncología Torácica (AAOC)

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-26
Primary Completion
2025-11-18
Completion
2025-11-18
FDA Drug
Yes

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07141563 on ClinicalTrials.gov